Pharos iBio파로스아이바이오
388870 · KOSDAQ · ₩388870 · 파로스아이바이오
₩5,780▼ ₩110 (1.87%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | — | — | ₩0 |
| Cost of sales | — | — | ₩0 |
| Gross profit | — | — | ₩0 |
| Operating income | −₩12B | −₩13B | −₩10B |
| Net income | −₩11B | −₩11B | −₩8.9B |
| Net income to shareholders | −₩11B | −₩10B | −₩8.9B |
Balance sheet
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Total assets | ₩30B | ₩20B | ₩30B |
| Current assets | ₩26B | ₩16B | ₩26B |
| Cash and equivalents | ₩26B | ₩6.4B | ₩16B |
| Total liabilities | ₩16B | ₩1B | ₩1.3B |
| Current liabilities | ₩1.4B | ₩973M | ₩1.2B |
| Borrowings | ₩7.7B | ₩124M | ₩0 |
| Total equity | ₩14B | ₩19B | ₩28B |
| Shareholders' equity | ₩14B | ₩19B | ₩28B |
Cash flow
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Cash from operations | −₩8.3B | −₩9.3B | −₩7.4B |
| Capital spending | ₩15M | ₩677M | ₩840M |
| Free cash flow | −₩8.4B | −₩10B | −₩8.3B |
Consolidated where available. Amounts in won.
Also known as: Pharos iBio / 파로스아이바이오 / 388870 / KRX:388870
Source: KRX statistical information